Eton Pharmaceuticals, Inc. — Q1 2020 Form 10-Q
Reporting period: Three months ended March 31, 2020. Financial amounts below are in thousands of dollars, except per-share data. The interim financial statements are unaudited.
Business context and reporting period
Eton is a specialty pharmaceutical company developing and commercializing prescription products, primarily through the FDA’s 505(b)(2) pathway. Biorphen, approved in October 2019 and launched in December 2019, was its only revenue-generating product in the quarter. The company also has a pipeline of hospital-based and pediatric oral-liquid products.
Key financial metrics
| Metric | Q1 2020 | Q1 2019 / comparison |
|---|---|---|
| Revenue | $99, all product sales | $500, all licensing revenue |
| Cost of product sales; gross profit (loss) | $102; $(3) | $0; $500 |
| Research and development | $6,268 | $6,465 |
| General and administrative | $2,610 | $1,589 |
| Operating loss | $(8,881) | $(7,554) |
| Net loss; loss per share | $(9,049); $(0.50) | $(7,410); $(0.42) |
| Net cash used in operating activities | $(7,217) | $(6,767) |
At March 31, 2020, cash and cash equivalents were $12,335, inventory $1,726, total current assets $15,341, and total current liabilities $2,051. Total assets were $17,241 and stockholders’ equity was $10,620. Long-term debt, net of discount and including accrued fees, was $4,570; the credit agreement’s gross principal was $5,000. The company reported no income-tax expense. No separate operating margin guidance was provided.
Material changes versus the prior comparable period
- Revenue shifted from $500 of one-time licensing revenue in Q1 2019 to $99 of Biorphen product sales in Q1 2020. Management said Biorphen sales were then the company’s only revenue source.
- Net loss widened by $1,639. G&A rose $1,021, principally due to higher compensation, Biorphen marketing and distribution costs, and legal costs associated mainly with a Paragraph IV patent challenge. R&D decreased $197; 2020 included $4,764 of Alkindi Sprinkle licensing expense.
- Operating cash use increased by $450. Management cited increased G&A, inventory stocking for Biorphen, and timing of regulatory filing fees and development milestone payments.
- Cash increased by $269 during the quarter, primarily because of $7,459 net proceeds from a March common-stock offering. The company issued 2.5 million shares at $3.00 per share; shares outstanding were 20,761,960 at quarter-end, versus 17,877,486 at year-end 2019.
- Inventory increased to $1,726 from $380 at year-end 2019. Accounts receivable declined to $205 from $473.
Guidance, outlook, risks and unusual items
- Liquidity outlook: Management believed cash on hand and expected Biorphen sales would fund operating expenses and capital requirements for at least 12 months from the financial statements’ issuance date. This estimate depends on sales and spending assumptions; the company cautioned it could use capital sooner and may need additional financing.
- Pipeline and licensing: Under its March 2020 agreement, Eton obtained U.S. marketing rights to Alkindi Sprinkle, whose NDA was under FDA review with a September 29, 2020 PDUFA date. The initial licensing fee was $3,500 cash plus 379,474 shares valued at $1,264, expensed in R&D. Management expected additional product revenue in the latter part of 2020 and beyond; this was an expectation, not quantified guidance.
- Debt terms: The amended SWK facility allowed an additional $2,000 draw and up to $3,000 more upon specified FDA approvals. Borrowings bear interest at three-month LIBOR plus 10%, subject to a 2% floor; the agreement requires a minimum $3,000 cash balance, is secured by company assets, and includes covenants and limits on additional debt.
- COVID-19: The company warned the pandemic could materially adversely affect development, regulatory review, suppliers, manufacturing, distribution, sales-force promotion, hospital use of Biorphen, access to capital, and liquidity. The extent and duration were uncertain.
- Subsequent events: On April 2, Eton sold 100,000 shares for $300 net proceeds. On May 4, it received a $361 Paycheck Protection Program loan, with 1% interest and potential forgiveness. These occurred after quarter-end.
- Other items: The filing reported no pending or threatened litigation known to have a material operational impact and no off-balance-sheet transactions. The company disclosed related-party product arrangements involving entities affiliated with its CEO; it terminated the Andersen Agreement in April 2020 with no payment due.
Important facts for investors to verify
- Whether Biorphen sales grow sufficiently to support management’s stated cash-runway estimate, including the effects of returns, chargebacks, discounts, and distribution fees.
- Cash burn, inventory levels, financing needs, and compliance with the SWK facility’s minimum-cash and other covenants.
- FDA decisions and timing for Alkindi Sprinkle and other pipeline candidates, and the commercial and financial terms of their licensing arrangements.
- The operational and financial effects of COVID-19 on hospital demand, product supply, regulatory timelines, and access to capital.
- The potential dilution from equity financing, outstanding warrants and options, and any further share issuance.